Well they are really still "limping" with cash even after the CR completely reliant on a partner to fund any further trial advancement with the exception of the small add-on for 1103. Funding the company "until the end of 2015" would really just be treading water with minimal expenditure so let's hope they secure deals with partners taking up the R&D outlay for trials so they can actually move forward.
Well they are really still "limping" with cash even after the CR...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $41.71K | 393.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 375093 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 177753 | 1 |
View Market Depth
| Last trade - 13.38pm 18/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |